AP2201A - Sustained-release tablet composition of pramipexole. - Google Patents

Sustained-release tablet composition of pramipexole.

Info

Publication number: AP2201A
Authority: AP; ARIPO
Prior art keywords: pramipexole; sustained; release tablet; tablet composition; composition
Prior art date: 2002-07-25

Application number

AP2005003205A

Other languages

English (en)

Other versions

AP2005003205A0 (en

Inventor

Gregory E Amidon

John M Heimlich

Ernest J Lee

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-25

Filing date

2003-07-25

Publication date

2011-01-24

2003-07-25 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2005-03-31 Publication of AP2005003205A0 publication Critical patent/AP2005003205A0/xx

2011-01-24 Application granted granted Critical

2011-01-24 Publication of AP2201A publication Critical patent/AP2201A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

AP2005003205A 2002-07-25 2003-07-25 Sustained-release tablet composition of pramipexole. AP2201A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US39842702P	2002-07-25	2002-07-25
US39844702P	2002-07-25	2002-07-25
US47951303P	2003-06-18	2003-06-18

Publications (2)

Publication Number	Publication Date
AP2005003205A0 AP2005003205A0 (en)	2005-03-31
AP2201A true AP2201A (en)	2011-01-24

Family

ID=31192087

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003205A AP2201A (en)	2002-07-25	2003-07-25	Sustained-release tablet composition of pramipexole.

Country Status (41)

Country	Link
US (2)	US20050226926A1 (fr)
EP (2)	EP1531814B1 (fr)
JP (1)	JP4700963B2 (fr)
KR (1)	KR100712832B1 (fr)
CN (1)	CN1313092C (fr)
AP (1)	AP2201A (fr)
AR (1)	AR040681A1 (fr)
AT (1)	ATE406162T1 (fr)
AU (1)	AU2003261241B2 (fr)
BR (1)	BR0312960A (fr)
CA (1)	CA2492854C (fr)
CR (1)	CR7661A (fr)
CU (1)	CU23440B7 (fr)
CY (1)	CY1110408T1 (fr)
DE (1)	DE60323235D1 (fr)
DK (1)	DK1531814T3 (fr)
EA (2)	EA200702187A1 (fr)
EC (1)	ECSP055568A (fr)
ES (1)	ES2310673T3 (fr)
GE (1)	GEP20074048B (fr)
HK (1)	HK10777456A1 (fr)
HR (1)	HRP20041235B1 (fr)
IL (1)	IL166078A0 (fr)
IS (1)	IS7623A (fr)
MA (1)	MA27328A1 (fr)
ME (1)	MEP52308A (fr)
MX (1)	MXPA05001054A (fr)
MY (1)	MY138846A (fr)
NO (1)	NO334298B1 (fr)
NZ (1)	NZ537790A (fr)
OA (1)	OA13303A (fr)
PA (1)	PA8578301A1 (fr)
PE (1)	PE20040130A1 (fr)
PL (1)	PL215587B1 (fr)
PT (1)	PT1531814E (fr)
RS (1)	RS51719B (fr)
SI (1)	SI1531814T1 (fr)
TW (1)	TWI347849B (fr)
UY (1)	UY27912A1 (fr)
WO (1)	WO2004010997A1 (fr)
ZA (1)	ZA200500439B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060281797A1 (en) *	2001-12-11	2006-12-14	University Of Virginia Patent Foundation	Neurorestoration with R(+) Pramipexole
MXPA04005572A (es) *	2001-12-11	2004-12-06	Univ Virginia	Uso de pramipexol para tratamiento de esclerosis lateral amiotrofica.
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
MY136318A (en) *	2002-07-25	2008-09-30	Pharmacia Corp	Sustained-release tablet composition
PA8578501A1 (es) *	2002-07-25	2005-02-04	Pharmacia Corp	Forma de dosificacion una vez al dia de pramipexol
WO2005005484A1 (fr)	2003-07-11	2005-01-20	Asahi Kasei Chemicals Corporation	Poudre amylacee fonctionnelle
EA200700388A1 (ru)	2004-08-13	2007-08-31	Бёрингер Ингельхайм Интернациональ Гмбх	Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
PT1781260E (pt) *	2004-08-13	2010-12-20	Boehringer Ingelheim Int	Formulação em comprimido de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável, um método para a preparação do mesmo e sua utilização
JP4814885B2 (ja) *	2004-09-09	2011-11-16	サイコファルマ，エッセ．エ．デセ．ウヴェ．	ヒドララジン持続放出用医薬組成物および該組成物を含む癌治療薬
EP1731514A1 (fr) *	2005-06-02	2006-12-13	Sandoz AG	Méthode de préparation du pramipexole
AU2006279643B2 (en) *	2005-08-15	2010-06-17	University Of Virginia Patent Foundation	Neurorestoration with R(+) pramipexole
US20090041844A1 (en) *	2006-02-10	2009-02-12	Boehringer Ingelheim International Gmbh	Modified Release Formulation
WO2007090883A1 (fr) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Formulation à libération prolongée
WO2007090882A2 (fr) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Compositions pharmaceutiques
WO2007121188A2 (fr) *	2006-04-10	2007-10-25	Knopp Neurosciences, Inc.	Compositions et procédés d'utilisation de r(+)-pramipexole
US8518926B2 (en)	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
CA2652251A1 (fr) *	2006-05-16	2007-11-29	Knopp Neurosciences, Inc.	Compositions de r(+) et s(-) pramipexole et procedes d'utilisation de celles-ci
WO2008001204A2 (fr) *	2006-06-29	2008-01-03	Antares Pharma Ipl Ag	Compositions transdermiques de pramipexole présentant des propriétés de perméation améliorées
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) *	2007-03-14	2013-08-27	Knopp Neurosciences, Inc.	Synthesis of chirally purified substituted benzothiazole diamines
EP2150239A1 (fr) *	2007-04-24	2010-02-10	Boehringer Ingelheim International GmbH	Combinaison comprenant une préparation de comprimés à libération prolongée, contenant du pramipexole ou un de ses sels pharmaceutiquement acceptable
WO2008150741A1 (fr) *	2007-06-04	2008-12-11	Drugtech Corporation	Compositions d'agoniste de dopamine à libération contrôlée
EP2291178A4 (fr) *	2008-06-09	2013-07-24	Supernus Pharmaceuticals Inc	Formulations à libération contrôlée de pramipexole
EP2334185A4 (fr)	2008-08-19	2011-09-21	Knopp Neurosciences Inc	Compositions et procédés employant du (r)-pramipexole
CN102802418A (zh) *	2009-06-19	2012-11-28	诺普神经科学股份有限公司	用于治疗肌萎缩性侧索硬化的组合物和方法
MX2012000096A (es) *	2009-07-02	2012-04-02	Supernus Pharmaceuticals Inc	Un metodo de tratamiento de un trastorno neurologico.
WO2011037976A2 (fr) *	2009-09-22	2011-03-31	Dr. Reddy's Laboratories Limited	Formulations pharmaceutiques de pramipexole
WO2011086182A2 (fr)	2010-01-18	2011-07-21	Synthon Bv	Comprimés à libération prolongée de pramipexole
TR201001862A1 (tr)	2010-03-11	2011-10-21	Sanovel �La� San.Ve T�C.A.�.	Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
WO2011148243A1 (fr)	2010-05-24	2011-12-01	Lupin Limited	Formulation à libération prolongée de pramipexole
KR101307334B1 (ko) *	2010-07-02	2013-09-12	주식회사 바이오파마티스	프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013034173A1 (fr)	2011-09-06	2013-03-14	Synthon Bv	Comprimés à libération prolongée de pramipexole
US9512096B2 (en)	2011-12-22	2016-12-06	Knopp Biosciences, LLP	Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (fr)	2012-11-15	2014-05-21	Aristo Pharma GmbH	Comprimé de pramipexol à libération prolongée
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
HUE054185T2 (hu)	2013-07-12	2021-08-30	Knopp Biosciences Llc	Eozinofilek és/vagy bazofilek megemelkedett szintjének kezelése
WO2015023786A1 (fr)	2013-08-13	2015-02-19	Knopp Biosciences Llc	Compositions et méthodes de traitement de troubles des cellules plasmatiques et de troubles prolymphocytaires à cellules b
US9763918B2 (en)	2013-08-13	2017-09-19	Knopp Biosciences Llc	Compositions and methods for treating chronic urticaria
CN103520128B (zh)	2013-10-12	2018-08-21	石家庄杏林锐步医药科技股份有限公司	一种普拉克索的缓释片剂、制备方法及其用途
IL312486B1 (en)	2017-04-10	2025-01-01	Chase Therapeutics Corp	NK1 antagonist combination and method for treating synucleinopathies
KR20250004125A (ko)	2017-06-30	2025-01-07	체이스 테라퓨틱스 코포레이션	우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN109316466B (zh) *	2017-07-31	2022-04-05	深圳翰宇药业股份有限公司	一种盐酸普拉克索缓释制剂及其制备方法
CN111212640A (zh)	2017-08-17	2020-05-29	顾自强	单胺抗帕金森药物的双羟萘酸盐、其制备方法及其用途
CN113876729B (zh) *	2021-11-11	2023-05-30	南通联亚药业股份有限公司	一种盐酸普拉克索缓释片剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4731374A (en) *	1984-12-22	1988-03-15	Dr. Karl Thomae Gmbh	Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
WO1999016442A2 (fr) *	1997-09-30	1999-04-08	Pharmacia & Upjohn Company	Formulation de comprimes a degagement prolonge pour le traitement de la maladie de parkinson
EP0933079A1 (fr) *	1998-02-03	1999-08-04	Cerestar Holding Bv	Amidon s'écoulant librement, directement compressible comme liant, désintégrant et charge pour comprimés par compression et capsules en gélatine dure
US6277875B1 (en) *	2000-07-17	2001-08-21	Andrew J. Holman	Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US15735A (en) *		1856-09-16		Improvement in harvesters
US2887440A (en) *	1957-08-12	1959-05-19	Dow Chemical Co	Enteric coating
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja)	1975-07-24	1983-01-06	武田薬品工業株式会社	Ｌ− アスコルビンサンセイザイノセイゾウホウ
US4140755A (en)	1976-02-13	1979-02-20	Hoffmann-La Roche Inc.	Sustained release tablet formulations
CH649215A5 (de)	1981-04-29	1985-05-15	Hoffmann La Roche	Pharmazeutische praeparate.
SE8103843L (sv)	1981-06-18	1982-12-19	Astra Laekemedel Ab	Farmaceutisk mixtur
US4424235A (en)	1981-09-14	1984-01-03	Hoffmann-La Roche Inc.	Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
DE3447075A1 (de) *	1984-12-22	1986-07-03	Dr. Karl Thomae Gmbh, 7950 Biberach	Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US4738851A (en)	1985-09-27	1988-04-19	University Of Iowa Research Foundation, Inc.	Controlled release ophthalmic gel formulation
US4709712A (en)	1986-10-22	1987-12-01	Dermatalogical Products Of Texas	Polycarboxylic acid polymer gels as protective agents
GB8828020D0 (en)	1988-12-01	1989-01-05	Unilever Plc	Topical composition
US5026559A (en)	1989-04-03	1991-06-25	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5273975A (en)	1989-06-09	1993-12-28	The Upjohn Company	Heterocyclic amines having central nervous system activity
DE69016430T2 (de)	1989-06-09	1995-06-01	Upjohn Co	Heterozyklische amine mit zns-wirksamkeit.
GB9015822D0 (en)	1990-07-18	1990-09-05	Beecham Group Plc	Compositions
US5472712A (en) *	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) *	1992-04-29	1997-08-12	Warner-Lambert Company	Dual control sustained release drug delivery systems and methods for preparing same
US5431920A (en)	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) *	1994-03-02	1995-10-17	Andrx Pharmaceuticals, Inc.	Controlled release tablet formulation
WO1997004752A1 (fr) *	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Compositions pharmaceutiques d'oestrogenes conjugues et leurs modes d'emploi
AU729529B2 (en)	1997-06-06	2001-02-01	Depomed, Inc.	Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
EA002482B1 (ru) *	1997-07-01	2002-06-27	Пфайзер Инк.	Соли сертралина и лекарственные формы с длительным высвобождением сертралина
US5895663A (en)	1997-07-31	1999-04-20	L. Perrigo Company	Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (fr) *	1997-08-14	1999-02-14	Francois Carriere	Preparation d'un amidon riche en amylose pregelatinise et deramifie utile comme excipient pour la liberation prolongee de principes actifs
DE69819748T2 (de)	1997-09-12	2004-09-30	Columbia Laboratories (Bermuda) Ltd.	Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en)	1998-08-25	2001-06-19	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en)	1998-08-25	2003-09-23	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US7153845B2 (en)	1998-08-25	2006-12-26	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US6056977A (en) *	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
NZ505807A (en)	1998-03-11	2003-01-31	Smithkline Beecham Corp	Controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride; useful for the treatment or prophylaxis of dementia
GB9812426D0 (en)	1998-06-10	1998-08-05	Reckitt & Colmann Prod Ltd	Improvements in or relating to organic compositions
TW407058B (en) *	1998-07-17	2000-10-01	Dev Center Biotechnology	Oral cisapride dosage forms with an extended duration
DE19906290A1 (de)	1999-02-15	2000-08-17	Falk Pharma Gmbh	Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US7374779B2 (en)	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CN1208090C (zh) *	1999-03-31	2005-06-29	詹森药业有限公司	在控制释放制剂中的预胶凝淀粉
DE19927688A1 (de) *	1999-06-17	2000-12-21	Gruenenthal Gmbh	Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
EA200801805A1 (ru)	1999-07-01	2008-12-30	Фармация Энд Апджон Компани	Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
AU5060499A (en)	1999-08-04	2001-03-05	Ranbaxy Laboratories Limited	Hydrodynamically balanced oral drug delivery system
US6387403B1 (en)	1999-09-15	2002-05-14	Alza Corporation	Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
WO2001022820A1 (fr)	1999-09-30	2001-04-05	The General Hospital Corporation	Utilisation de pramipexole pour traiter l'etat de besoin de cocaine
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PL355391A1 (en) *	1999-12-22	2004-04-19	Pharmacia Corporation	Sustained-release formulation of a cyclooxygenase-2 inhibitor
CA2332691C (fr)	2000-01-27	2007-11-27	The York Group, Inc.	Systeme de mise en marche pour services funeraires
WO2001062236A2 (fr)	2000-02-24	2001-08-30	Pharmacia & Upjohn Company	Nouvelles combinaisons medicamenteuses
ES2187249B1 (es)	2000-09-18	2004-09-16	Synthon Bv	Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv)	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
DE10138275A1 (de)	2001-08-10	2003-02-27	Boehringer Ingelheim Pharma	Verbindungen zur Beseitigung der Anhedonie
JP2005516020A (ja)	2001-12-20	2005-06-02	ファルマシア・コーポレーション	ゼロ次持続放出剤形およびその製造方法
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
MY136318A (en)	2002-07-25	2008-09-30	Pharmacia Corp	Sustained-release tablet composition
JP2005538105A (ja)	2002-07-25	2005-12-15	ファルマシア・コーポレーション	水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
PA8578501A1 (es)	2002-07-25	2005-02-04	Pharmacia Corp	Forma de dosificacion una vez al dia de pramipexol
US20040121010A1 (en)	2002-10-25	2004-06-24	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
AU2003224467A1 (en)	2003-03-11	2004-09-30	Korea United Pharm, Inc.	Process for the preparing of hardcapsule formulation containing lansoprazole
BRPI0408999A (pt)	2003-04-04	2006-03-28	Pharmacia Corp	comprimidos prensados de multiparticulados de liberação oral prolongada
US20050020589A1 (en)	2003-06-18	2005-01-27	Pfizer Inc.	Sustained-release tablet composition comprising a dopamine receptor agonist
EA200700388A1 (ru)	2004-08-13	2007-08-31	Бёрингер Ингельхайм Интернациональ Гмбх	Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
PT1781260E (pt)	2004-08-13	2010-12-20	Boehringer Ingelheim Int	Formulação em comprimido de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável, um método para a preparação do mesmo e sua utilização
WO2006046256A1 (fr)	2004-10-27	2006-05-04	Alembic Limited	Formulation a liberation prolongee de dihydrochlorure de pramipexole
WO2007002518A1 (fr)	2005-06-23	2007-01-04	Spherics, Inc.	Formes de dosage de pramipexole a liberation retardee ou a liberation prolongee/retardee
CA2613631A1 (fr)	2005-06-23	2007-01-04	Spherics, Inc.	Formes de dosage ameliorees pour le traitement de troubles moteurs
AU2006279643B2 (en)	2005-08-15	2010-06-17	University Of Virginia Patent Foundation	Neurorestoration with R(+) pramipexole
WO2007054976A2 (fr)	2005-11-08	2007-05-18	Panacea Biotec Ltd.	Nouvelles compositions pharmaceutiques a liberation controlee a base de lipides
US20090041844A1 (en)	2006-02-10	2009-02-12	Boehringer Ingelheim International Gmbh	Modified Release Formulation
WO2007090883A1 (fr)	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Formulation à libération prolongée
WO2007090882A2 (fr)	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Compositions pharmaceutiques
EP1886665A1 (fr)	2006-08-01	2008-02-13	Boehringer Ingelheim Pharma GmbH & Co. KG	Système thérapeutique gastro-retentif

2003
- 2003-07-23 US US10/626,166 patent/US20050226926A1/en not_active Abandoned
- 2003-07-24 MY MYPI20032784A patent/MY138846A/en unknown
- 2003-07-24 PA PA20038578301A patent/PA8578301A1/es unknown
- 2003-07-24 PE PE2003000734A patent/PE20040130A1/es not_active Application Discontinuation
- 2003-07-24 AR AR20030102666A patent/AR040681A1/es unknown
- 2003-07-25 GE GEAP8599A patent/GEP20074048B/en unknown
- 2003-07-25 EA EA200702187A patent/EA200702187A1/ru unknown
- 2003-07-25 NZ NZ537790A patent/NZ537790A/en unknown
- 2003-07-25 EP EP03771807A patent/EP1531814B1/fr not_active Expired - Lifetime
- 2003-07-25 CA CA002492854A patent/CA2492854C/fr not_active Expired - Fee Related
- 2003-07-25 RS YU20050059A patent/RS51719B/sr unknown
- 2003-07-25 DK DK03771807T patent/DK1531814T3/da active
- 2003-07-25 BR BR0312960-8A patent/BR0312960A/pt not_active IP Right Cessation
- 2003-07-25 PL PL375696A patent/PL215587B1/pl unknown
- 2003-07-25 OA OA1200500016A patent/OA13303A/en unknown
- 2003-07-25 SI SI200331350T patent/SI1531814T1/sl unknown
- 2003-07-25 PT PT03771807T patent/PT1531814E/pt unknown
- 2003-07-25 CN CNB038178737A patent/CN1313092C/zh not_active Expired - Fee Related
- 2003-07-25 JP JP2004524787A patent/JP4700963B2/ja not_active Expired - Fee Related
- 2003-07-25 ME MEP-523/08A patent/MEP52308A/xx unknown
- 2003-07-25 KR KR1020057001392A patent/KR100712832B1/ko not_active IP Right Cessation
- 2003-07-25 AP AP2005003205A patent/AP2201A/xx active
- 2003-07-25 MX MXPA05001054A patent/MXPA05001054A/es active IP Right Grant
- 2003-07-25 TW TW092120406A patent/TWI347849B/zh not_active IP Right Cessation
- 2003-07-25 WO PCT/US2003/023205 patent/WO2004010997A1/fr active IP Right Grant
- 2003-07-25 AT AT03771807T patent/ATE406162T1/de active
- 2003-07-25 AU AU2003261241A patent/AU2003261241B2/en not_active Ceased
- 2003-07-25 DE DE60323235T patent/DE60323235D1/de not_active Expired - Lifetime
- 2003-07-25 EP EP08159203A patent/EP1987832A1/fr not_active Withdrawn
- 2003-07-25 ES ES03771807T patent/ES2310673T3/es not_active Expired - Lifetime
- 2003-07-25 EA EA200500079A patent/EA009663B1/ru not_active IP Right Cessation
- 2003-07-31 UY UY27912A patent/UY27912A1/es not_active Application Discontinuation
2004
- 2004-12-29 IS IS7623A patent/IS7623A/is unknown
- 2004-12-30 HR HRP20041235AA patent/HRP20041235B1/hr not_active IP Right Cessation
- 2004-12-30 IL IL16607804A patent/IL166078A0/xx unknown
2005
- 2005-01-06 NO NO20050093A patent/NO334298B1/no not_active IP Right Cessation
- 2005-01-17 ZA ZA200500439A patent/ZA200500439B/xx unknown
- 2005-01-24 EC EC2005005568A patent/ECSP055568A/es unknown
- 2005-01-24 CR CR7661A patent/CR7661A/es unknown
- 2005-01-25 CU CU20050018A patent/CU23440B7/es not_active IP Right Cessation
- 2005-01-25 MA MA28066A patent/MA27328A1/fr unknown
- 2005-11-08 HK HK05109947A patent/HK10777456A1/xx unknown
2008
- 2008-10-13 CY CY20081101125T patent/CY1110408T1/el unknown
2010
- 2010-03-03 US US12/716,755 patent/US8399016B2/en not_active Expired - Lifetime

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4731374A (en) *	1984-12-22	1988-03-15	Dr. Karl Thomae Gmbh	Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
WO1999016442A2 (fr) *	1997-09-30	1999-04-08	Pharmacia & Upjohn Company	Formulation de comprimes a degagement prolonge pour le traitement de la maladie de parkinson
EP0933079A1 (fr) *	1998-02-03	1999-08-04	Cerestar Holding Bv	Amidon s'écoulant librement, directement compressible comme liant, désintégrant et charge pour comprimés par compression et capsules en gélatine dure
US6277875B1 (en) *	2000-07-17	2001-08-21	Andrew J. Holman	Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

Also Published As

Publication number	Publication date
AP2005003205A0 (en)	2005-03-31
AU2003261241A1 (en)	2004-02-16
EA200702187A1 (ru)	2008-06-30
SI1531814T1 (sl)	2008-12-31
CN1671382A (zh)	2005-09-21
US8399016B2 (en)	2013-03-19
RS51719B (sr)	2011-10-31
WO2004010997A8 (fr)	2005-02-24
MA27328A1 (fr)	2005-05-02
IL166078A0 (en)	2006-01-15
AR040681A1 (es)	2005-04-13
GEP20074048B (en)	2007-02-26
KR20050062516A (ko)	2005-06-23
CY1110408T1 (el)	2015-04-29
JP2005538106A (ja)	2005-12-15
EA200500079A1 (ru)	2005-06-30
PA8578301A1 (es)	2004-07-20
US20050226926A1 (en)	2005-10-13
US20100316710A1 (en)	2010-12-16
JP4700963B2 (ja)	2011-06-15
OA13303A (en)	2007-04-13
EA009663B1 (ru)	2008-02-28
MEP52308A (en)	2011-02-10
HRP20041235A2 (en)	2005-06-30
EP1987832A1 (fr)	2008-11-05
KR100712832B1 (ko)	2007-04-30
BR0312960A (pt)	2005-06-14
NO20050093L (no)	2005-02-24
IS7623A (is)	2004-12-29
PL375696A1 (en)	2005-12-12
CN1313092C (zh)	2007-05-02
HRP20041235B1 (hr)	2013-07-31
DE60323235D1 (de)	2008-10-09
RS20050059A (en)	2007-08-03
MY138846A (en)	2009-07-31
NZ537790A (en)	2005-10-28
PL215587B1 (pl)	2013-12-31
CA2492854C (fr)	2009-10-20
PT1531814E (pt)	2008-10-29
AU2003261241B2 (en)	2009-06-18
NO334298B1 (no)	2014-01-27
TWI347849B (en)	2011-09-01
HK10777456A1 (en)	2007-11-30
CU23440B7 (es)	2009-10-16
PE20040130A1 (es)	2004-03-06
ECSP055568A (es)	2005-04-18
CA2492854A1 (fr)	2004-02-05
TW200418523A (en)	2004-10-01
ZA200500439B (en)	2006-08-30
EP1531814A1 (fr)	2005-05-25
DK1531814T3 (da)	2008-10-13
EP1531814B1 (fr)	2008-08-27
CR7661A (es)	2005-06-08
MXPA05001054A (es)	2005-04-08
ATE406162T1 (de)	2008-09-15
UY27912A1 (es)	2004-02-27
ES2310673T3 (es)	2009-01-16
WO2004010997A1 (fr)	2004-02-05

Publication	Publication Date	Title
AP2201A (en)	2011-01-24	Sustained-release tablet composition of pramipexole.
HK1077753A1 (en)	2006-02-24	Sustained-release tablet comprising reboxetine
AP2223A (en)	2011-03-24	Pramipexole once-daily dosage form.
GB0218625D0 (en)	2002-09-18	Pharmaceutical compounds
HK1082909A1 (en)	2006-06-23	Controlled-release drug composition
GB0215775D0 (en)	2002-08-14	Pharmaceutical compounds
IL166607A (en)	2014-07-31	Granule fungicide formulation
GB0221513D0 (en)	2002-10-23	Novel compounds and processes
DE60209673D1 (de)	2006-05-04	Tablettenbeschichtungen
AU149625S (en)	2002-10-21	Ring
PL377377A1 (pl)	2006-02-06	Nowe związki aminobenzofenonu
IL163778A0 (en)	2005-12-18	Processes for the synthesis of chloroadenosine andmethylthioadenosine
PL356853A1 (en)	2004-05-17	Application of bacteriphages
PL379864A1 (pl)	2006-11-27	Tabletki bromowodorku citalopramu
AU148729S (en)	2002-08-05	Tablet
AU148728S (en)	2002-08-05	Tablet
AU148730S (en)	2002-08-05	Tablet
GB0219744D0 (en)	2002-10-02	Tablet compositions
ZA200408338B (en)	2005-11-02	Heterocyclic compounds.
SI1537210T1 (sl)	2006-08-31	Lazna oligonukleotidna inhibicija ekspresije CD40
GB2392981B (en)	2004-08-11	Barometer
SI1509241T1 (sl)	2007-02-28	Nove uporabe cefaibolov
EP1511485A4 (fr)	2006-04-12	Utilisations nouvelles de i dl /i -tetrahydropalmatine
AU147738S (en)	2002-05-06	Ring
ZA200407363B (en)	2006-02-22	Novel compounds.